Reuters logo
BRIEF-Vistagen gives cardiac stem cell technologies sublicense to BlueRock Therapeutics
December 14, 2016 / 12:10 PM / a year ago

BRIEF-Vistagen gives cardiac stem cell technologies sublicense to BlueRock Therapeutics

Dec 14 (Reuters) - Vistagen Therapeutics Inc:

* Vistagen Therapeutics grants exclusive sublicense of cardiac stem cell technologies to BlueRock Therapeutics

* Vistagen Therapeutics Inc - Vistagen will receive an upfront cash payment of $1.25 million, as well as potential future milestone payments and royalties Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below